Finance

Launched by Pharmacyclics vets, preclinical cancer start-up Biomea Fusion seeks short path to IPO

Menin inhibitor moving toward clinic three months after series A

As its moves a menin inhibitor toward the clinic, Biomea has filed to go public three months after its series A round.

Less than